Regeneron Deal History & Licensing Activity
Regeneron is a large biotech headquartered in US. Over the past three years, Regeneron has been involved in 9 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (4 deals). The company currently has 50 active clinical trials, primarily in Cardiovascular.
Deals (12mo)
6
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Cardiovascular
Regeneron Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Regeneron in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Regeneron Pharmaceuticals | ADC | Discovery | collaboration | Aug 13, 2026 |
| Probody/Veloci-Bi conditionally activated bispecifics — Amendment No. 4 (two newly nominated programs, options on six more) | Regeneron Pharmaceuticals | Bispecific Antibodies | Preclinical | collaboration | May 29, 2026 |
| Telix Pharmaceuticals radiopharma pact | Regeneron Pharmaceuticals, Inc. | Radiopharmaceuticals | Discovery | collaboration | Apr 13, 2026 |
| TSRA-196 (AATD) | Tessera Therapeutics | Gene Therapy | Preclinical | co development | Dec 1, 2025 |
| lentiviral-vector CAR-T program | JW Therapeutics | Cell Therapy | Unknown | collaboration | Oct 30, 2025 |
| Undisclosed | ModeX Therapeutics | Bispecific Antibodies | Discovery | collaboration | Oct 29, 2025 |
Regeneron Pipeline Focus
Therapeutic areas and modalities where Regeneron is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Regeneron Strategic Signals
Key indicators of Regeneron's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Revenue at Risk (LOE)
Patent expirations create urgency for Regeneron to replace revenue through in-licensing or acquisitions.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Regeneron Clinical Pipeline
Regeneron has 50 active clinical trials across 6 development phases.
4
Unknown
2
Phase 4
8
Phase 1
9
Phase 1/2
7
Phase 2
20
Phase 3
See How Your Asset Matches Regeneron's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Regeneron Licensing & Deal Activity
Regeneron is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, Regeneron ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Regeneron include Cardiovascular (10 deals and trials), Hematological Malignancies (8 deals and trials), Oncology (6 deals and trials), and Metabolic (6 deals and trials). In terms of modality, Regeneron has shown particular interest in bispecific antibodies, cell therapy, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Regeneron and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Regeneron's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.